A multicentre implementation trial of an Artificial Intelligence-driven biomarker to inform Shared decisions for androgen deprivation therapy in men undergoing prostate radiotherapy: the ASTuTE protocol.

Journal: BMC cancer
PMID: 39948585

Abstract

BACKGROUND: Androgen deprivation therapy (ADT) improves outcomes in men undergoing definitive radiotherapy for prostate cancer but carries significant toxicities. Clinical parameters alone are insufficient to accurately identify patients who will derive the most benefit, highlighting the need for improved patient selection tools to minimize unnecessary exposure to ADT's side effects while ensuring optimal oncological outcomes. The ArteraAI Prostate Test, incorporating a multimodal artificial intelligence (MMAI)-driven digital histopathology-based biomarker, offers prognostic and predictive information to aid in this selection. However, its clinical utility in real-world settings has yet to be measured prospectively.

Authors

  • Eric Wegener
    GenesisCare Lake Macquarie Private Hospital, 3 Sydney St Lake Macquarie, Gateshead, NSW, 2290, Australia. eric.wegener@genesiscare.com.
  • Michael Ng
    Research Division for Mathematical and Statistical Science, University of Hong Kong, Hong Kong, China.
  • Mario Guerrieri
    Genesis Cancer Care Victoria, Ringwood, Australia; Ringwood Private Hospital, Ringwood East, Australia.
  • Timothy N Showalter
    Artera Inc., Los Altos, CA, USA; University of Virginia, Charlottesville, VA, USA.
  • Jeremy de Leon
    GenesisCare St Vincent's Hospital, Level A, 438 Victoria Street, Darlinghurst, NSW, 2010, Australia.
  • Sagar Ramani
    GenesisCare John Flynn Private Hospital, 42 Inland Drive, Tugun, QLD, 4224, Australia.
  • Marcus Dreosti
    Tennyson Centre, GenesisCare Kurralta Park, 520 South Road, Kurralta Park, SA, 5037, Australia.
  • Tee Lim
    GenesisCare Fiona Stanley Hospital, 102-118 Murdoch Drive, Murdoch, WA, 6150, Australia.
  • Bradley Wong
    GenesisCare Buderim, 10 King Street, Buderim, QLD, 4556, Australia.
  • Michael Chao
    Genesis Cancer Care Victoria, Ringwood, Australia; The Austin Hospital, Heidelberg, Australia; Ringwood Private Hospital, Ringwood East, Australia; University of Melbourne, Melbourne, Australia. Electronic address: Michael.Chao@genesiscare.com.
  • Kathryn Hogan
    GenesisCare St Vincent's Hospital, Level A, 438 Victoria Street, Darlinghurst, NSW, 2010, Australia.
  • Avi Raman
    Lingard Specialist Centre, Suite 3/2 Lingard St, Merewether, NSW, 2291, Australia.
  • Scott McClintock
    Gold Coast Private Hospital, Level 3, 123 Nerang St, Southport, QLD, 4215, Australia.
  • Darren Foreman
    College of Medicine and Public Health, Flinders University, Bedford Park, South Australia, Australia.
  • Matthew Brown
    St John of God Wexford Medical Centre, 3 Barry Marshall Parade, Murdoch, 6150, WA, Australia.
  • Stephen McCombie
    St John of God Wexford Medical Centre, 3 Barry Marshall Parade, Murdoch, 6150, WA, Australia.
  • Kevin McMillan
    Knox Private Hospital, 262 Mountain Hwy, Wantirna, VIC, 3152, Australia.
  • Kieran Beattie
    Nepean Urology Research Group, Nepean Hospital, Penrith New South Wales, Australia.
  • Mark Frydenberg
    Urology Department, Monash Cancer Centre, Monash Health, Melbourne, Australia. Electronic address: mark.frydenberg@monash.edu.
  • Lih-Ming Wong
    Melbourne Urology Group, Suite 2, 141 Grey Street, East Melbourne, Australia.
  • Dickon Hayne
    Medical School, The University of Western Australia, Perth, Australia.
  • John Yaxley
    Department of Medicine, University of Queensland, Brisbane, Australia; Wesley Urology Clinic, Brisbane, Australia.
  • Phillip Stricker
    Department of Urology, St. Vincent's Hospital, Sydney, Australia.
  • Jarad Martin
    Department of Radiation Oncology, Calvary Mater Newcastle, Newcastle, New South Wales, Australia.

Keywords

External Resources

Popular Topics
Recent Journals